New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
05:55 EDTPPHM, PPHMPeregrine management to meet with Roth Capital
Meeting to be held in Boston on February 22 hosted by Roth Capital.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
08:17 EDTPPHMPeregrine announces presentation of anti-tumor effects of PS blockade
Subscribe for More Information
April 20, 2015
08:06 EDTPPHMPeregrine reports bavituximab induces immune activation
Peregrine Pharmaceuticals announced the presentation of data from clinical translational studies of the company's phosphatidylserine, or PS,-targeting immunotherapy bavituximab. Initial data from a pilot study of clinical translational ex vivo cultures show that bavituximab, both alone and with docetaxel, elicits evidence of a tumor-specific immune response in patients with human adenocarcinoma of the lung and that bavituximab exhibits an impact on tumors with negative PD-L1 expression. Bavituximab is currently being evaluated in second-line non-small cell lung cancer, or NSCLC, as part of the SUNRISE pivotal Phase III clinical trial.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use